

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED: Central Indiana Cancer Centers 1346 East County Line Road Indianapolis, IN 46227	2. NRC/REGIONAL OFFICE U.S. Nuclear Regulatory Commission Region III 2443 Warrenville Road, Suite 210 Lisle, Illinois 60532-4351
REPORT NUMBER(S) 2006-001 & 2006-002	

3. DOCKET NUMBER(S) 030-35383	4. LICENSEE NUMBER(S) 13-32241-01	5. DATE(S) OF INSPECTION April 18, 2006
----------------------------------	--------------------------------------	--------------------------------------------

LICENSEE:
The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection

- 1. Based on the inspection findings, no violations were identified.
- 2. Previous violation(s) closed.
- 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, NUREG-1600, to exercise discretion, were satisfied.

_____ Non-Cited Violation(s) was/were discussed involving the following requirement(s) and Corrective Action(s):

- 4. During this inspection certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.

(Violations and Corrective Actions)

Licensee's Statement of Corrective Actions for Item 4, above.

I hereby state that, within 30 days, the actions described by me to the inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

Title	Printed Name	Signature	Date
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Deborah A. Piskura		04/18/2006

Docket File Information
SAFETY INSPECTION REPORT
AND COMPLIANCE INSPECTION

1. LICENSEE Cental Indiana Cancer Centers		2. NRC/REGIONAL OFFICE Region III 2443 Warrenville Road, Suite 210 Lisle, IL 60532	
REPORT NUMBER(S) 2006-001 and 2006-002			
3. DOCKET NUMBER(S) 030-35383	4. LICENSE NUMBER(S) 13-32241-01	5. DATE(S) OF INSPECTION April 18, 2006	
6. INSPECTION PROCEDURES 87132		7. INSPECTION FOCUS AREAS 03.01, 03.02, 03.03, 03.04, 03.05, 03.06, 03.07, and 03.08	
SUPPLEMENTAL INSPECTION INFORMATION			
1. PROGRAM CODE(S) 02240	2. PRIORITY G 2	3. LICENSEE CONTACT Yun Wang, Ph.D., RSO	4. TELEPHONE NUMBER 317.883.3909
<input checked="" type="checkbox"/> Main Office Inspection		Next Inspection Date: <u>April 2008</u>	
<input checked="" type="checkbox"/> Field <u>6845 Rama Drive, Indpls, IN</u>			
<input type="checkbox"/> Temporary Job Site _____			

PROGRAM SCOPE

This licensee was private multi-speciality out-patient cancer care clinic. Licensed activities were authorized at four facilities located in the Indianapolis metropolitan area. The licensee was authorized use materials specified in Sections 35.100, 35.200, 35.300, 35.400 (limited to prostate permanent implants), Ir-192 in an HDR unit, Cs-137 in an instrument calibrator unit, and I-125 for the Gliasite radiotherapy system. This inspection was conducted at the facilities located at 1346 East County Line Road, Indianapolis, Indiana (main clinic) and the Radiation Therapy Department, 6845 Rama Drive, Indianapolis, Indiana.

The licensee's nuclear medicine procedures were performed ^{at} the Rama Drive location. The department was staffed with one full-time technologist who performed 50+ cancer follow-up studies monthly (bones, MUGAs). Typically, in a year the licensee administered 5-7 iodine-131 thyroid carcinoma treatments. The licensee obtained its I-131 in capsule form only. The department also administered 20 Sm-153 dosages for treatment of metastatic bone disease, 2 I-125 Gliasite procedures, and 4 Y-90 Zevalin treatments annually.

The licensee possessed a Nucletron Model 105.999 MicroSelectron transportable HDR unit. The licensee transported its HDR unit with a portable "treatment cart" to its customer locations on a monthly basis. The radiation therapy department was staffed with 2 medical physicists, 2 dosimetrists, and 6 physicians (authorized users) and 16 therapy technologists. The licensee administered approximately 200 patient treatment series annually using its HDR unit; these treatments were for bronchial, prostate, and gynecological cancers. All HDR patient treatments were administered by the attending radiation oncologist and the medical physicist (therapy technologists did not operate the controls to the HDR unit). Source exchange, maintenance, and repairs on the HDR unit were performed by the manufacturer.

This inspection consisted of interviews with selected licensee personnel, a review of selected records, tour of the nuclear medicine and radiation oncology departments, and independent measurements. The inspector observed one HDR brachytherapy treatment. The inspector reviewed the written directive for the procedure; observed the licensee performing daily QA checks and treatment planning; and observed the patient treatment and patient surveys at the conclusion of the treatment. The inspector also interviewed the physician authorized user and nurse who attended the patient.